HIV can develop resistance to lenacapavir, but at a cost to the virus
 Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game…
Giant amoeba-infecting viruses offer new clues to the origin of eukaryotic life
The origin of life on Earth becomes even more fascinating and complex as we peer into the mysterious…
New method could improve manufacturing of gene-therapy drugs | MIT News
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their…
Unveiling the dual role of HIV integrase in viral replication
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most…